title: Retrospective comparative study of the effects of dendritic cell vaccine and cytokine-induced killer cell immunotherapy with that of chemotherapy alone and in combination for colorectal cancer.
abstract: OBJECTIVE
  This retrospective study determined the delayed-type hypersensitivity (DTH) skin test and safety of dendritic cell (DC) vaccine and cytokine-induced killer (CIK) cell immunotherapy and the survival compared to chemotherapy in 239 colorectal cancer (CRC) patients.
  
  
  METHODS
  DTH and safety of the immunotherapy were recorded. The overall survival (OS) and disease free survival curves were compared according to the immunotherapy and/or chemotherapy received with Kaplan-Meier estimates.
  
  
  RESULTS
  Of the 70 patients who received immunotherapy, 62.86% had a positive DTH skin test, 38.57% developed fever, 47.14% developed insomnia, 38.57% developed anorexia, 4.29% developed joint soreness, and 11.43% developed skin rash. For 204 resectable CRC patients, median survival time (MST) (198.00 days) was significantly longer in patients with immunotherapy plus chemotherapy than with chemotherapy alone (106.00 days) (P = 0.02). For 35 patients with unresectable or postsurgery relapsed CRC and who were confirmed to be dead, no statistical difference was observed in the MST between the patients treated with immunotherapy and with chemotherapy (P = 0.41). MST in the patients treated with chemotherapy plus immunotherapy was 154 days longer than that of patients treated with chemotherapy alone (P = 0.41).
  
  
  CONCLUSIONS
  DC vaccination and CIK immunotherapy did not cause severe adverse effects, induce immune response against CRC, and prolong OS.
authors.affiliation: Department of Oncology, Tianjin Union Medicine Center, No. 190 Jieyuan Road, Hongqiao District, Tianjin 300121, China.
authors.forename: Jingxiu
authors.initials: J
authors.lastname: Niu
authors.affiliation: Shanghai Claison Biotechnology Co. Ltd., Shanghai, China.
authors.forename: Yanjie
authors.initials: Y
authors.lastname: Ren
authors.affiliation: Shanghai Claison Biotechnology Co. Ltd., Shanghai, China.
authors.forename: Tianyu
authors.initials: T
authors.lastname: Zhang
authors.affiliation: Shanghai Claison Biotechnology Co. Ltd., Shanghai, China.
authors.forename: Xuejing
authors.initials: X
authors.lastname: Yang
authors.affiliation: Department of Oncology, Tianjin Union Medicine Center, No. 190 Jieyuan Road, Hongqiao District, Tianjin 300121, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhu
authors.affiliation: Department of Oncology, Tianjin Union Medicine Center, No. 190 Jieyuan Road, Hongqiao District, Tianjin 300121, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Zhu
authors.affiliation: Department of Oncology, Tianjin Union Medicine Center, No. 190 Jieyuan Road, Hongqiao District, Tianjin 300121, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Oncology, Tianjin Union Medicine Center, No. 190 Jieyuan Road, Hongqiao District, Tianjin 300121, China.
authors.forename: Jiali
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Oncology, Tianjin Union Medicine Center, No. 190 Jieyuan Road, Hongqiao District, Tianjin 300121, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Pang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019496:Cancer Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D055612:Cytokine-Induced Killer Cells / Q000276:immunology / Q000637:transplantation; D003713:Dendritic Cells / Q000276:immunology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging
chemical_list: D019496:Cancer Vaccines